{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:21:32Z","timestamp":1762957292055,"version":"3.37.3"},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of radioactive iodine in the treatment of hyperthyroidism is common\n                    practice. However, a standardized treatment protocol with regard to radioactive\n                    iodine treatment (RAI) remains subject to discussion. We retrospectively\n                    analyzed 100 patient records. Patient diagnosis, age, gender, body mass index\n                    (BMI), dose of radioactive iodine, thyroid size, the 24\u2009h radioiodine\n                    uptake (24\u2009h RAIU) and protein bound iodine (PBI) were deducted, as well\n                    as the use of antithyroid drugs prior to RAI. Biochemical parameters were\n                    obtained, such as TSH, fT4, fT3, Anti-TPO, Anti-TG antibodies and thyroid\n                    stimulating antibodies. After 5 years of follow-up, 46% of the patients\n                    proved to be hypothyroid, whereas 8% of the patients were not cured\n                    after one dose of RAI. One year after RAI, a larger proportion of patients with\n                    a toxic nodule developed hypothyroidism compared to patients with a multinodular\n                    goiter (MNG) (44.2% vs. 21.2%). Radioactive iodine dose, PBI,\n                    RAIU, BMI, size of the thyroid gland, diagnosis, age and TPO-antibodies showed\n                    statistically significant differences in the development of hypothyroidism.\n                    Furthermore, thiamazole pretherapy was shown to be a predictor of\n                    hypothyroidism, as well as a high PBI value, exhibiting a positive predictive\n                    value of 85.2% when the PBI exceeded 0.16. We suggest a standardized\n                    measurement of TPO-Ab\u2019s to further determine their role in the\n                    development of hypothyroidism after RAI. The empirical dosing regimen was very\n                    effective, illustrating a 92% cure rate after 1 dose.<\/jats:p>","DOI":"10.1055\/a-2205-2052","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:56:16Z","timestamp":1699318576000},"page":"134-141","source":"Crossref","is-referenced-by-count":1,"title":["The Presence of Anti-TPO Antibodies Increase the Likelihood of\n                    Post-I131 Hypothyroidism"],"prefix":"10.1055","volume":"56","clinical-trial-number":[{"clinical-trial-number":"nct04663451","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5550-2599","authenticated-orcid":false,"given":"Felix","family":"Quataert","sequence":"additional","affiliation":[{"name":"Dermatology, UZ Brussel, Brussel, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"Bravenboer","sequence":"additional","affiliation":[{"name":"Endocrinology, UZ Brussel, Brussel, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marleen","family":"Keyaerts","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, UZ Brussel, Brussel, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina Emilia","family":"Andreescu","sequence":"additional","affiliation":[{"name":"Endocrinology, UZ Brussel, Brussel, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"P N Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.11604\/pamj.2018.29.48.13655","article-title":"Pattern of presentation of Graves' disease and response to radioiodine\n                    therapy in South African men","volume":"29","author":"Y A Onimode","year":"2018","journal-title":"Pan Afr Med J"},{"key":"ref3","first-page":"206","article-title":"Classification and etiology of hyperthyroidism","volume":"36","author":"K \u0141acka","year":"2014","journal-title":"Pol Merkur Lekarski"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/RLU.0b013e3182817c78","article-title":"High failure rates after (131)I therapy in Graves hyperthyroidism patients with\n                    large thyroid volumes, high iodine uptake, and high iodine turnover","volume":"38","author":"J A de Jong","year":"2013","journal-title":"Clin Nucl Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of\n                    hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"D S Ross","year":"2016","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/nm.2000.4597","article-title":"Therapeutic options in the management of toxic and nontoxic nodular goiter","volume":"30","author":"J E Freitas","year":"2000","journal-title":"Semin Nucl Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EJE-14-0608","article-title":"Recombinant human TSH and radioactive iodine therapy in the management of benign\n                    multinodular goiter","volume":"172","author":"H Graf","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.307.6908.828","article-title":"Radioiodine treatment of multinodular non-toxic goitre","volume":"307","author":"B Nygaard","year":"1993","journal-title":"BMJ"},{"key":"ref9","first-page":"623","article-title":"Hyperthyroidism: diagnosis and treatment","volume":"72","author":"J R Reid","year":"2005","journal-title":"Am Fam Physician"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3803\/EnM.2016.31.1.168","article-title":"Comparison of fixed versus calculated activity of radioiodine for the treatment\n                    of Graves disease in adults","volume":"31","author":"A U Canto","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5455\/medarh.2017.71.270-273","article-title":"Incidence of hypothyreoidism after radioactive iodine-I131 treatment in\n                    dependance of hyperthyreoidism etiology and therapy dose","volume":"71","author":"N Beslic","year":"2017","journal-title":"Med Arch"},{"key":"ref12","first-page":"1587","article-title":"Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated\n                    activity levels in elderly patients with thyroid cancer","volume":"47","author":"R M Tuttle","year":"2006","journal-title":"J Nucl Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/bmj.1.5389.1005","article-title":"Thyrotoxicosis treated by surgery or iodine-131. With special reference to\n                    development of hypothyroidism","volume":"1","author":"M Green","year":"1964","journal-title":"Br Med J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41430-020-00766-5","article-title":"Urinary sodium and iodine concentrations among Belgian adults: results from the\n                    first national Health Examination Survey","volume":"75","author":"S Vandevijvere","year":"2021","journal-title":"Eur J Clin Nutr"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1530\/eje.0.1460767","article-title":"Objective estimates of the probability of developing hypothyroidism following\n                    radioactive iodine treatment of thyrotoxicosis","volume":"146","author":"A M Ahmad","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4183\/aeb.2017.72","article-title":"Dynamic changes of TRAb and TPOAb after radioiodine therapy in Graves'\n                    disease","volume":"13","author":"Q Dong","year":"2017","journal-title":"Acta Endocrinol (Buchar)"},{"key":"ref17","first-page":"432","article-title":"Hypothyroidism and its associated factors after radioactive iodine therapy among\n                    patients with hyperthyroidism in the Northeast Coast State of Malaysia","volume":"13","author":"WM I Wan Mohamed","year":"2018","journal-title":"J Taibah Univ Med Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/ajm.AJM_161_16","article-title":"Etiologies and posttreatment conditions of thyrotoxic patients in Sylhet\n                    division, Bangladesh: a clinical series","volume":"7","author":"M K Mahmud","year":"2017","journal-title":"Avicenna J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1210\/jc.2015-1026","article-title":"Thiamazole pretreatment lowers the (131)I activity needed to cure\n                    hyperthyroidism in patients with nodular goiter","volume":"100","author":"A Kyrilli","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","first-page":"3488","article-title":"The effect of methimazole pretreatment on the efficacy of radioactive iodine\n                    therapy in Graves' hyperthyroidism: one-year follow-up of a prospective,\n                    randomized study","volume":"86","author":"V A Andrade","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4103\/2230-8210.139234","article-title":"Radioiodine therapy in patients with Graves' disease and the effects of\n                    prior carbimazole therapy","volume":"18","author":"A Karyampudi","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"ref22","first-page":"1815","article-title":"Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in\n                    hyperthyroidism","volume":"37","author":"R Aktay","year":"1996","journal-title":"J Nucl Med"},{"key":"ref23","first-page":"17","article-title":"Dosing of radioactive iodine in end-stage renal disease patient with thyroid\n                    cancer","author":"M Bhat","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref24","first-page":"47","article-title":"Effect of administrated activity, admission number and TSH level on radiation\n                    retention curve of patients taking iodine-131 therapy for differentiated thyroid\n                    carcinoma: Looking beyond established regulations","author":"M Moslehi","year":"2018","journal-title":"Iran J Nucl Med"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2205-2052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:21:46Z","timestamp":1730805706000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2205-2052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":24,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2205-2052","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"type":"print","value":"0018-5043"},{"type":"electronic","value":"1439-4286"}],"subject":[],"published-other":{"date-parts":[[2023,11,6]]},"published":{"date-parts":[[2023,11,6]]}}}